News
NIH inventors have developed the first pharmacologic option for developmental stuttering, which is currently only managed by speech therapy, but addresses a $3 billion underserved global market. This technology uses small-molecule iron chelators – drugs that bind and remove excess iron – for the
NIH will host a free virtual workshop titled Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer. This workshop will discuss the policies and practices that shape biomedical innovation and promote access to NIH-funded discoveries. It will also cover how
Inventors at the National Institute of Dental and Craniofacial Research (NIDCR) are searching for a collaboration partner for a tissue engineering method for treating cartilage damage. Currently, there are no effective treatment options approved to prevent arthritis progression. This method involves
The Public Health and Economic Impact Study of NIH Intramural Technology Transfer Licensing final project report has been published. This report dives into the history of biomedical innovations that were a result of the NIH Intramural Research Program (IRP) that benefit the United States. This